Cost-Effectiveness of Pre-emptive DPYD Genotyping Compared to Standard of Care Among Patients Receiving Fluoropyrimidine-Based Anti-cancer Treatment in Australia
This Australian single-arm study demonstrated that pre-emptive PGx screening prevents severe, fatal FP-related toxicities and hospitalisations and is likely to be cost effective. Our findings suggest the value of PGx screening and warrant implementation and reimbursement within Australian healthcare settings.
Authors
- Jennifer Martin (ORCID: https://orcid.org/0000-0002-8614-0199)
- Maarten J. IJzerman (ORCID: https://orcid.org/0000-0001-5788-5805)
- Marliese Alexander (ORCID: https://orcid.org/0000-0001-5782-7912)
- Craig R. Underhill (ORCID: https://orcid.org/0000-0001-9335-2678)
- Chloe Georgiou
- Sam Harris (ORCID: https://orcid.org/0000-0002-1861-9069)
- Mark Warren (ORCID: https://orcid.org/0000-0002-7941-5254)
- Senthil Lingaratnam (ORCID: https://orcid.org/0000-0003-2678-5208)
- Sarah Glewis (ORCID: https://orcid.org/0000-0002-7764-5427)
- Mussab Fagery (ORCID: https://orcid.org/0000-0003-4095-8590)
- Jeanne Tie (ORCID: https://orcid.org/0000-0001-9244-2057)
- Robert M. Campbell (ORCID: https://orcid.org/0000-0003-2120-6887)
- Michael Michael (ORCID: https://orcid.org/0000-0002-0593-2662)
Institutions
- The University of Melbourne (AU)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Cancer Council Victoria (AU)
- Parks Victoria (AU)
- Peter MacCallum Cancer Centre (AU)
- Albury Wodonga Health (AU)
- Bendigo Health (AU)
- Melbourne Health (AU)
- Melbourne Genomics Health Alliance (AU)
- University of Newcastle Australia (AU)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Clinical Drug Investigation
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1007/s40261-025-01489-w
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00